ABL1 and leukemia: Additionally, dual inhibitors that target both JAK2 and other signaling molecules implicated in leukemia, such as FLT3, BCR-ABL, or RAS, may provide a more comprehensive therapeutic approach for patients with relapsed or refractory leukemia[61].